| Gleason 7 (3+4) n/N (%) | Gleason 7 (4+3) n/N (%) | p value | |
| Preoperative serum PSA | |||
| ≤ 4,00ng/ml | 0 | 0 | 0.06 |
| > 4,00 and ≤ 9,99ng/ml | 5/7 (71) | 2/7 (29) | |
| > 9,99ng/ml | 2/7 (29) | 5/7 (71) | |
| Percentage of gland involvement by carcinoma | |||
| ≤ 10% | 2/11 (18) | 0 | 0.03 |
| > 10% and ≤ 20% | 5/11 (46) | 2/9 (22) | |
| > 20% and ≤ 30% | 2/11 (18) | 3/9 (33) | |
| > 30% and ≤ 40% | 2/11 (18) | 3/9 (33) | |
| > 60% and ≤ 80% | 0 | 1/9 (11) | |
| Positive circumferential surgical margin | 4/11 (36) | 4/9 (44) | 1.00 |
| Positive basal surgical margin | 0 | 4/9 (44) | 0.03 |
| Positive apical surgical margin | 3/11 (27) | 0 | 0.22 |
| Extraprostatic extension | 2/11 (18) | 5/9 (56) | 0.15 |
| Seminal vesicle invasion | 1/11 (9) | 4/9 (44) | 0.12 |
| Ki-67 immunostaining (% of cancer cells) | |||
| Negative | 2/11 (18) | 0 | 0.04 |
| > 0% and ≤ 3,0% | 9/11(82) | 7/9 (78) | |
| > 3,0% | 2/9 (22) |